Zhongwei Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhongwei Lv has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Aimin Yang
Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
15 shared publications - Bin Liu
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China
15 shared publications - Feng Shi
Hunan Cancer Hospital 1 , Changsha, China
15 shared publications - Guang Chen
34Department of Thyroid Surgery, The First Hospital of Jilin University, Changchun, China
15 shared publications - Guihua Wang
35Department of Oncology, Changsha Central Hospital, Changsha, China
15 shared publications - Hui Yang
Henan Cancer Hospital 2 , Zhengzhou, China
15 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure10 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 10 provides representative immunofluorescence images showing elevated levels of TNF-α, IFN-γ, and IL-2 in Hepa1-6 tumor tissues after combination treatment. File 11 (你的复发模型照片).
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure10 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 10 provides representative immunofluorescence images showing elevated levels of TNF-α, IFN-γ, and IL-2 in Hepa1-6 tumor tissues after combination treatment. File 11 (你的复发模型照片).
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure1 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 1 outlines the detailed flow cytometry gating strategies used to identify various immune cell populations in this study.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure1 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 1 outlines the detailed flow cytometry gating strategies used to identify various immune cell populations in this study.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
PTC596 has been studied in advanced solid tumors in clinical trials. However, the effects of PTC596 alone or in combination with programmed cell death protein 1 (PD-1) blockade in hepatocellular carcinoma (HCC) remain unclear. Subcutaneous tumor models in both Balb/c and C57BL/6 mice were used to evaluate the effects of PTC596 alone or combined with an anti–PD-1 antibody (anti–PD-1) on tumor growth control, survival, and tumor-infiltrating immune cells. The underlying mechanism was investigated by immunofluorescence, flow cytometry, RNA sequencing (RNA-seq), and IHC. We found that PTC596 not only killed HCC cells in vitro but also controlled H22 and Hepa1-6 tumor growth in vivo. PTC596 promoted the infiltration of CD8+ T cells in H22 and Hepa1-6 models. Importantly, combination therapy (PTC596 plus anti–PD-1) showed superior antitumor efficacy and prolonged mouse survival. Moreover, combination therapy induced robust antitumor immune activity by activating mature dendritic cells, CD8+ T cells, natural killer cells, inflammatory monocytes, and total macrophages while suppressing the infiltration of B cells and M2-type macrophages. RNA-seq confirmed that the antitumor effects of PTC596 alone or in combination with anti–PD-1 relied on the regulation of inflammation- and immune-associated pathways. Furthermore, combination therapy induced long-term immunologic memory in “cured” mice, as these mice were unaffected by tumor rechallenge after the original tumors were eliminated. Therefore, PTC596 is not only an effective antitumor drug for HCC but also supports the formation of a favorable tumor microenvironment that enhances the effect of PD-1 blockade. This study supports that PTC596 combined with PD-1 blockade could be a promising strategy for HCC.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
PTC596 has been studied in advanced solid tumors in clinical trials. However, the effects of PTC596 alone or in combination with programmed cell death protein 1 (PD-1) blockade in hepatocellular carcinoma (HCC) remain unclear. Subcutaneous tumor models in both Balb/c and C57BL/6 mice were used to evaluate the effects of PTC596 alone or combined with an anti–PD-1 antibody (anti–PD-1) on tumor growth control, survival, and tumor-infiltrating immune cells. The underlying mechanism was investigated by immunofluorescence, flow cytometry, RNA sequencing (RNA-seq), and IHC. We found that PTC596 not only killed HCC cells in vitro but also controlled H22 and Hepa1-6 tumor growth in vivo. PTC596 promoted the infiltration of CD8+ T cells in H22 and Hepa1-6 models. Importantly, combination therapy (PTC596 plus anti–PD-1) showed superior antitumor efficacy and prolonged mouse survival. Moreover, combination therapy induced robust antitumor immune activity by activating mature dendritic cells, CD8+ T cells, natural killer cells, inflammatory monocytes, and total macrophages while suppressing the infiltration of B cells and M2-type macrophages. RNA-seq confirmed that the antitumor effects of PTC596 alone or in combination with anti–PD-1 relied on the regulation of inflammation- and immune-associated pathways. Furthermore, combination therapy induced long-term immunologic memory in “cured” mice, as these mice were unaffected by tumor rechallenge after the original tumors were eliminated. Therefore, PTC596 is not only an effective antitumor drug for HCC but also supports the formation of a favorable tumor microenvironment that enhances the effect of PD-1 blockade. This study supports that PTC596 combined with PD-1 blockade could be a promising strategy for HCC.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure11 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 11 contains photographs comparing the lack of tumor formation in combination therapy-cured mice with the rapid tumor growth in untreated mice after tumor rechallenge.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure11 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 11 contains photographs comparing the lack of tumor formation in combination therapy-cured mice with the rapid tumor growth in untreated mice after tumor rechallenge.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure2 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 2 shows the reduction of cell viability, proliferation, and migration in HepG2 and HCCLM3 cells following PTC596 administration.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure2 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 2 shows the reduction of cell viability, proliferation, and migration in HepG2 and HCCLM3 cells following PTC596 administration.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure3 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 3 displays the transcriptional profiles, including heatmaps, volcano plots, and enrichment analyses, of differentially expressed genes in PTC596-treated HepG2 and HCCLM3 cells.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure3 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 3 displays the transcriptional profiles, including heatmaps, volcano plots, and enrichment analyses, of differentially expressed genes in PTC596-treated HepG2 and HCCLM3 cells.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure6 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 6 details the in vivo RNA-sequencing analysis, including GO, Reactome, and KEGG pathway enrichment related to the immune response after PTC596 treatment.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure6 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 6 details the in vivo RNA-sequencing analysis, including GO, Reactome, and KEGG pathway enrichment related to the immune response after PTC596 treatment.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure4 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 4 demonstrates that PTC596 treatment at various doses has no significant adverse effects on mouse body weight or kidney and liver functions.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure4 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 4 demonstrates that PTC596 treatment at various doses has no significant adverse effects on mouse body weight or kidney and liver functions.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure5 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 5 illustrates the increased infiltration of CD8+ T cells in the H22-bearing mouse model following PTC596 treatment, as shown by immunohistochemistry.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure5 from Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
Supplementary Figure 5 illustrates the increased infiltration of CD8+ T cells in the H22-bearing mouse model following PTC596 treatment, as shown by immunohistochemistry.